Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model
Drug-eluting embolic transarterial chemoembolization (DEE-TACE) improves the overall survival of hepatocellular carcinoma (HCC), but the agents used are not tailored to HCC. Our patented liposomal formulation enables the loading and elution of targeted therapies onto DEEs. This study aimed to establ...
Main Authors: | Nadine Abi-Jaoudeh, Ben Sadeghi, Hanna Javan, Jim Na, Graham Beaton, Fabio Tucci, Satheesh Ravula, David K. Imagawa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/12/3236 |
Similar Items
-
The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer
by: Yonghua Bi, et al.
Published: (2022-11-01) -
BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started
by: V. V. Breder, et al.
Published: (2018-07-01) -
Role of drug-eluting beads versus conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
by: Mahmoud Abu Elfadl, et al.
Published: (2019-01-01) -
Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma
by: Yonghua Bi, et al.
Published: (2021-05-01) -
Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
by: Su Min Cho, et al.
Published: (2021-04-01)